[HTML][HTML] Immunotherapy: a promising approach for glioma treatment

F Yasinjan, Y Xing, H Geng, R Guo, L Yang… - Frontiers in …, 2023 - frontiersin.org
Gliomas are the most prevalent primary malignant brain tumors worldwide, with
glioblastoma (GBM) being the most common and aggressive type. Despite two decades of …

[HTML][HTML] Advances in glioblastoma therapy: an update on current approaches

RS Angom, NMR Nakka, S Bhattacharya - Brain sciences, 2023 - mdpi.com
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …

[HTML][HTML] Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies

A Hamad, GM Yusubalieva, VP Baklaushev… - Viruses, 2023 - mdpi.com
Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

[HTML][HTML] New directions in the therapy of glioblastoma

K Szklener, M Mazurek, M Wieteska, M Wacławska… - Cancers, 2022 - mdpi.com
Simple Summary Despite the continuous development of treatment technology,
glioblastoma remains a challenge for modern medicine. The standard of care remains a …

[HTML][HTML] Immunotherapy in glioblastoma: current approaches and future perspectives

U Sener, MW Ruff, JL Campian - International Journal of Molecular …, 2022 - mdpi.com
Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality
treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields …

[HTML][HTML] Macrophages in recurrent glioblastoma as a prognostic factor in the synergistic system of the tumor microenvironment

N Montemurro, B Pahwa, A Tayal, A Shukla… - Neurology …, 2023 - mdpi.com
Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous
system in adults. Ever more recent papers are focusing on understanding the role of the …

[HTML][HTML] Immunotherapy in glioblastoma treatment: Current state and future prospects

SLR Pinheiro, FFB Lemos, HS Marques… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Glioblastoma remains as the most common and aggressive malignant brain tumor, standing
with a poor prognosis and treatment prospective. Despite the aggressive standard care …

Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma

B Dufrusine, E Capone, S Ponziani… - Molecular …, 2023 - Wiley Online Library
Glioblastoma multiforme (GBM) is a lethal disease characterized by an overall survival of
about 1 year, making it one of the most aggressive tumours, with very limited therapeutic …

[HTML][HTML] Glioblastoma multiforme

T Kanderi, V Gupta - StatPearls [Internet], 2022 - ncbi.nlm.nih.gov
Glioblastoma Multiforme - StatPearls - NCBI Bookshelf US flag An official website of the United
States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …

AKIP1 accelerates glioblastoma progression through stabilizing EGFR expression

S Wan, C Liu, C Li, Z Wang, G Zhao, J Li, W Ran… - Oncogene, 2023 - nature.com
Abstract A Kinase Interacting Protein 1 (AKIP1) is found to be overexpressed in a variety of
human cancers and associated with patients' worse prognosis. Several studies have …